Reporter Staff

Reporter Staff

| This email address is being protected from spambots. You need JavaScript enabled to view it.
The University of Alabama at Birmingham (UAB), in collaboration with Novo Nordisk, is conducting a 3-year research study to see if CagriSema, an investigational weekly medicine being studied for the treatment of obesity is also safe for the heart and blood vessels.

We are doing this study to see if CagriSema (Cagrilintide/semaglutide), a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.

You may qualify to participate if::
  • You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral
  • arterial disease)
  • You are 55 years of age or older
  • You are living with obesity (BMI ≥ 30 kg/m2 )
  • You can have type 2 diabetes and/or chronic kidney disease
  • You are able to attend regular clinic visits and receive phone calls over
  • a period of 3 years

Want to know more about the REDEFINE 3 study?
Call the study team at (205) 996-4015 or via email ccnrn@uab.edu

Tatyana Gavrikova, Sherry Polhill and Aparna Tamhane are the fourth-quarter 2022 honorees of the UAB Shared Values in Action Program, which honors those whose work exemplifies and embodies Forging the Future's shared values. Nominations for first-quarter 2023 honorees are open through Feb. 28.

If you’re being treated for MDD and your current antidepressant medication(s) is not working, the SAVITRI Study might interest you. The SAVITRI Study is researching a potential MDD therapy to improve symptoms of depression, and you may be able to participate. This research study is now enrolling adults diagnosed with MDD. Those who qualify will receive the investigational medication (or placebo), study-specific medical exams, and study-specific laboratory tests at no cost. Participants in the SAVITRI Study must: be 18 to 65 years of age; have a clinical diagnosis of MDD; be currently on antidepressant medication(s); have had inadequate response to up to 5 oral antidepressant medications; and fulfill other eligibility criteria. For more information, please call (205) 996-5987 or email lalexander@uabmc.edu. Please mention SAVITRI in your message.
Do you have a loved one with agitation associated with Alzheimer’s dementia? Is their agitation becoming overwhelming? Examples of some easily identifiable agitated behaviors are: restlessness, screaming, shouting, throwing things, resistiveness, constant unwarranted requests for attention or help, pacing/aimless wandering, kicking, hitting others or self, pushing people, hurting self or others, tearing things or destroying property. In this study, researchers want to find out if an investigational drug called AVP-786 is safe and effective (useful) in managing agitation in adults with Alzheimer’s dementia, when compared to a placebo. If you are a caregiver for a person with Alzheimer’s disease, please call (205) 996-5987 or email lalexander@uabmc.edu for more information.
The RECOVER study was designed in partnership with many of the nation’s top experts in treatment-resistant depression, and approved by Medicare, to provide additional evidence of the benefit of VNS Therapy. If the results confirm previous studies, Medicare and other insurers may start to cover it.

People who participate in RECOVER will receive VNS Therapy and all study-related care at no cost to them.

To join the RECOVER study, you must be 18 years or
older and:

1. Currently depressed
2. Have depression, or bipolar depression, that has lasted for at least two years or recurred several times
3. Have tried at least four types of antidepressant treatments and not found them helpful
4. Have Medicare Insurance

Employees can learn about compliance with the Americans with Disabilities and Rehabilitation acts, explore best practices for engaging with students with disabilities, and access key resources during a new online training from UAB Disability Support Services.

The UAB Department of Dermatology is seeking people for a clinical study looking into ultraviolet light induced effects on the skin immune responses. This study may provide clues for the prevention of skin cancer. We are seeking 18-35 year old individuals, without a history of skin cancer, who are capable of being sunburned and who are not currently pregnant or planning to become pregnant the next 2 months. Participants may receive up to $500 in compensation. Please contact 205-801-8841 or UVstudy@uabmc.edu for more information.
We are currently seeking Gulf War Veterans to participate in a brain imaging research study. Healthy Gulf War Veterans and Veterans with chronic health problems are invited to participate. Participation involves 1-2 visits to UAB for 2.5 hours total. Participants undergo MRI brain scan, blood draw, and complete several questionnaires. Participants who complete the study receive $150 compensation. Please email chloej@uab.edu or call 205-434-1502 for more information and to find out if you're eligible.
You may be eligible to participate in a research study about the effects of Exercise and Metoprolol (a blood pressure pill) on a protein in your blood. This protein is related to heart disease. Eligible participants must be Healthy African American men having no history of diabetes, heart problems, or kidney problems. The study involves performing the exercise, taking metoprolol, consuming prepared meals, and collecting blood samples. Participants will be compensated $350 for completing the study visits. Please e-mail at exercisebetastudy@uabmc.edu or call us at 205-934-7173 if you are interested.

Teresa Taber Doughty, Ph.D., who will begin April 3, brings to the role extensive experience in higher education and a demonstrated commitment to preparing outstanding education professionals; she has served as dean of the University of Texas at Arlington’s College of Education since 2016.

Page 1 of 53